Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05496036 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma

Study acronym: MCC
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 31, 2025 to Dec 31, 2026 Completion date: Sep 30, 2026 to Sep 30, 2027 · Site contact updatedv8 Show 2 more changesShow less
    • Completion date: Sep 30, 2026 to Sep 30, 2027
    • Site contact updated
  2. Re-verified, no change to tracked fieldsv7
  3. Primary completion date: Sep 30, 2024 to Dec 31, 2025v6
  4. Re-verified, no change to tracked fieldsv5
  5. Start date: Feb 8, 2023 to Feb 13, 2023v4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jan 1, 2023 to Feb 8, 2023 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Jan 1, 2023 to Feb 8, 2023
    • Site details revised
  2. Start date: Oct 1, 2022 to Jan 1, 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to determine the response of Merkel cell carcinoma to pembrolizumab before surgery and to determine whether it further reduces the risk for disease recurrence. Another purpose of this study is to look at the side effects that occur when the experimental drug pembrolizumab is given to people with Merkel cell carcinoma before and after their standard of care surgery to remove the Merkel cell carcinoma.
Trial Details
NCT Number NCT05496036
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Merck Sharp & Dohme LLC
Conditions Merkel Cell Carcinoma
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov